(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. John Shen discussing apalutamide for advanced prostate cancer in older patients. In TITAN and SPARTAN, apalutamide added to continuous androgen deprivation therapy (ADT) improved PSA response, radiographic progression-free survival (rPFS), metastasis-free survival (MFS), and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC)1 and nonmetastatic castration-resistant prostate cancer (nmCRPC).2,3 The objective of this analysis presented at the ESMO 2021 meeting was to assess the efficacy and safety of apalutamide in the TITAN and SPARTAN studies by patient age.